Drug Profile


Alternative Names: hpNSC; Human parthenogenetic neural stem cells - International Stem Cell Corporation; ISC-hpNSC

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University; International Stem Cell Corporation
  • Developer International Stem Cell Corporation; Tulane University
  • Class Antiparkinsonians; Cell therapies; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Brain injuries; Stroke

Most Recent Events

  • 07 May 2018 International Stem Cell Corporation has patent protection for the method of manufacture of ISC hpNSC in USA
  • 10 Apr 2018 International Stem Cell Corporation plans a phase II trial for Parkinson's disease in 2018
  • 13 Nov 2017 Efficacy and safety data from a phase I trial in Parkinson's disease released by International Stem Cell Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top